Company Number: 13030401

Analysis Date: 2025-07-20 11:45 UTC

1. Industry Classification
   Fairlight Pharma Limited operates under SIC code 47730, classified as "Dispensing chemist in specialised stores." This sector forms part of the wider pharmaceutical retail industry in the UK, characterized by the dispensing of prescription medicines and provision of pharmaceutical care in specialized pharmacy outlets. Key features of this sector include regulatory oversight by the Medicines and Healthcare products Regulatory Agency (MHRA) and the General Pharmaceutical Council (GPhC), a focus on compliance with NHS contractual frameworks, and competition from both independent pharmacies and large retail chains.

2. Relative Performance
   Fairlight Pharma Limited is a small private limited company, recently incorporated in late 2020, with a current share capital of £100. Financially, it shows a net asset base of £216,193 as of April 2024, reflecting a modest but steady increase from £57,669 in 2020. The company holds significant intangible assets (goodwill of approximately £525k), likely linked to acquisitions or business combination, and tangible assets of around £34k. Current asset levels stand at £406,776 with net current assets of £193,200, indicating positive working capital management. However, it carries substantial long-term liabilities (£535,147), primarily bank loans secured against property assets, which is typical for businesses investing in physical pharmacy locations.

Compared to typical industry metrics for small independent pharmacies, Fairlight Pharma's financial size and asset base are within expected norms. The industry often features narrow profit margins and capital-intensive operations due to regulatory compliance and inventory requirements. The steady increase in shareholders' funds and positive net assets suggest sound financial management for a business of its size and age.

3. Sector Trends Impact
   The UK pharmaceutical retail sector is currently impacted by several trends:

• Increased NHS Contractual Pressures: Community pharmacies face ongoing challenges from NHS reimbursement cuts and contractual changes, which pressure profitability.
• Digital Transformation: Growing consumer adoption of online prescription services and telehealth consultations is reshaping traditional dispensing models.
• Regulatory Compliance: Enhanced focus on safe dispensing and controlled drugs management requires continuous investment in staff training and technology.
• Consolidation and Competition: Larger chains and supermarkets continue consolidating market share, challenging independents to differentiate through specialized services.

Fairlight Pharma, as a specialized dispensing chemist, must navigate these dynamics by leveraging niche expertise and possibly expanding digital services or pharmacy-led patient care programs to maintain competitiveness.

4. Competitive Positioning
   Strengths:

• The company’s asset base, including goodwill, indicates potential acquisition of existing operations or brand value, providing a competitive foothold.
• Positive working capital and increasing equity demonstrate operational stability and capacity to invest in growth or compliance initiatives.
• Directors hold significant control and appear actively engaged, which can enable agile decision-making.

Weaknesses:

• The company has relatively high long-term debt secured against property, which could pressure cash flows in a low-margin environment.
• Limited scale with only 8 employees as of recent filings may constrain capacity compared to larger competitors.
• As a small private limited company, it may lack the bargaining power and economies of scale enjoyed by national chains.

In summary, Fairlight Pharma Limited is a niche player within the UK pharmacy dispensing sector, showing stable financial health relative to industry norms but operating in a challenging market environment dominated by larger competitors and evolving NHS frameworks.